The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index; 37 of the 51 sources its claims cite were checked for support.
Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors
Open accessAbstract
Purpose: We conducted a phase I/II study to evaluate durvalumab (D; anti-PD-L1) in combination with tremelimumab (T; anti–cytotoxic T-lymphocyte antigen 4) in pediatric patients with relapsed/refractory solid tumors. Patients and methods: The dose-finding phase (phase I) assessed the safety and pharmacokinetics of D+T at two dose levels to determine the recommended phase II dose (RP2D). The primary endpoint for the dose-expansion phase (phase II) was antitumor activity (by Response Evaluation Criteria in Solid Tumors v1.1) at the RP2D. Assessment of circulating cells reflecting immune cell activation was a secondary endpoint. Results: Based on safety and pharmacokinetic data in the dose-finding phase (n = 29), the adult-equivalent RP2D was determined as D (30 mg/kg) + T (1 mg/kg). In the dose-expansion phase, 21 patients (sarcoma, n = 11; solid tumors, n = 10) were treated at the RP2D. Of patients with sarcoma, none achieved an objective response and one had stable disease ≥7 weeks. Of the patients with solid tumors, one (chordoma) had a confirmed partial response (10.8 months duration) and one (renal cell carcinoma) had stable disease ≥7 weeks. Treatment-related adverse events occurred in 76% of patients (19% as grade 3 or 4). No adverse events leading to death were reported. Across both phases treatment with D+T resulted in an increase in CD4+Ki67+ T cells. Conclusions: D (30 mg/kg) + T (1 mg/kg) had limited antitumor activity in this pediatric population; however, the safety profile was manageable and consistent with the known safety profile in adult patients, with no new safety concerns identified. Clinical trial registration: ClinicalTrials.gov, identifier NCT03837899; EudraCT, identifier 2018-003118-42.
Overview
CoChat Summary
TL;DR
In pediatric patients with relapsed/refractory advanced solid tumors, durvalumab 30 mg/kg plus tremelimumab 1 mg/kg was selected as the adult-equivalent recommended phase II dose, with a manageable safety profile but limited antitumor activity. In the dose-expansion phase, the objective response rate was 5.0% among 20 evaluable patients, with one confirmed partial response in chordoma lasting 10.8 months.
Key findings
- The recommended phase II dose was durvalumab 30 mg/kg plus tremelimumab 1 mg/kg every 4 weeks, based on safety and pharmacokinetic data from 29 patients in the dose-finding phase.
- In the dose-expansion phase (n = 21; sarcoma n = 11, solid tumors n = 10), no sarcoma patient achieved an objective response; one sarcoma patient had stable disease ≥7 weeks. Among solid tumor patients, one chordoma patient had a confirmed partial response lasting 10.8 months and one renal cell carcinoma patient had stable disease ≥7 weeks.
- The ORR in the dose-expansion phase was 5.0% among 20 evaluable patients. Median PFS was 1.7 months in both the sarcoma cohort (90% CI, 1.6–1.9) and the solid tumor cohort (90% CI, 0.9–2.8); median OS was 6.6 months (90% CI, 1.9–15.8) and 6.9 months (90% CI, 1.6–not reached), respectively.
- Treatment-related adverse events occurred in 76% of dose-expansion patients, with 19% grade 3 or 4; no adverse events leading to death were reported. Across both phases, treatment increased CD4+Ki67+ T cells, with a transient rise at day 8 in 100% of evaluable patients.
Methods
- Open-label, international, multicenter phase I/II study in pediatric patients aged ≥1 to <18 years with relapsed/refractory malignant solid tumors, enrolled at 19 sites in seven countries from March 2019 through May 2022.
- Dose-finding used a modified 3 + 3 design incorporating pharmacokinetic exposure and dose-limiting toxicities to determine the RP2D; dose-expansion used a Simon-2 stage design for the sarcoma cohort and descriptive statistics for the heterogeneous solid tumor cohort.
- Primary endpoints were RP2D/safety in dose-finding and antitumor activity by RECIST v1.1 in dose-expansion; analyses were descriptive, with 90% CIs unless otherwise stated, exact Mid-P method for ORR, and Kaplan–Meier methods for PFS and OS.
Limitations
- The paper states that limited enrollment meant demographics were not reflective of a global pediatric population, with Black and Asian patients under-represented.
- The paper states that cross-trial comparisons with prior ICI studies are limited, and that conclusions about immune response differences between pediatric and adult patients are limited by overlapping CIs and small sample size.
- Evident from the text: this was a single-arm, open-label study without a comparator; dose-expansion cohorts were small (sarcoma n = 11, solid tumors n = 10), median treatment durations were short (1.84 and 1.72 months), and PD-L1 biomarker analysis was exploratory with only 27 evaluable tumor samples.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
26 Valid · 3 Not valid · 5 Not checked · 89 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“PD-L1 positivity was defined as >5% membrane staining and included the following tumors (in order of PD-L1 expression): alveolar rhabdomyosarcoma (86%), high-risk neuroblastoma (72%), Ewing sarcoma (57%), and osteosarcoma (50%).”
§ Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors > Introduction
What the sources say
- Disputedcites [15] Antonia, 2016, Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study, Lancet Oncol sourceExperimental — accuracy not yet measured
The Methods > Outcomes passage defines PD-L1 positivity as membrane staining in ≥25% of tumour cells, contrary to the claimed >5% threshold. The paper studies non-small-cell lung cancer; the retrieved Results passages do not report the stated pediatric tumour types or their percentages. Page numbers were not available in our copy. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainn = 115- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Unfortunately, to date, no objective responses have been reported with any ICI combination regimen in young children (age <10 years) with a solid tumor (8, 17).”
§ Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors > Discussion
What the sources say
- Partly supportedcites [8] Davis, 2022, A phase I/II trial of nivolumab plus ipilimumab in children and young adults with relapsed/refractory solid tumors: a Children’s Oncology Group Study ADVL1412, Clin Cancer Res sourceExperimental — accuracy not yet measured
The Results > Response section (page unavailable) reports two confirmed partial responses to nivolumab plus ipilimumab, in patients aged 25 and 18; neither was under 10. The paper supports the claim for its own trial, but does not establish that no objective responses have been reported with any ICI combination regimen in children under 10. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [17] Long, 2022, Checkpoint immunotherapy in pediatrics: here, gone, and back again, Am Soc Clin Oncol Educ Book source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“To date, limited antitumor activity with ICI monotherapies and dual PD-(L)1 and CTLA-4 inhibitor regimens has been observed in pediatric solid tumors (3, 6–8, 10–12).”
§ Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors > Discussion
What the sources say
- Partly supportedcites [3] Hutzen, 2019, Immunotherapies for pediatric cancer: current landscape and future perspectives, Cancer Metastasis Rev sourceExperimental — accuracy not yet measured
The Pembrolizumab and ipilimumab section reports low response rates to pembrolizumab monotherapy in pediatric soft-tissue and bone sarcomas. But the Future perspectives section says pediatric trials of combined PD-1/CTLA-4 blockade were underway and their data were still forthcoming; it does not report limited antitumor activity for those dual regimens. Page numbers were not provided in our copy. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [6] Geoerger, 2020, Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial, Lancet Oncol source
- Partly supportedcites [7] Davis, 2020, Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial, Lancet Oncol sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports no evidence of single-agent nivolumab activity in the non-lymphoma pediatric solid tumors studied, supporting the monotherapy portion. This single-arm trial does not report outcomes for dual PD-(L)1 and CTLA-4 inhibitor regimens, so it cannot support that portion of the sentence. (LLM, conf=0.90)
- Supportedcites [8] Davis, 2022, A phase I/II trial of nivolumab plus ipilimumab in children and young adults with relapsed/refractory solid tumors: a Children’s Oncology Group Study ADVL1412, Clin Cancer Res source
The Introduction says single-agent PD-1/PD-L1 activity in cancers arising in children and young adults has been limited, and that single-agent CTLA-4 blockade showed no significant antitumor activity in a pediatric solid-tumor trial. The Discussion reports a low overall objective response rate for this study’s dual PD-1/CTLA-4 regimen. The supplied passages have section labels but no page numbers. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [10] Geoerger, 2020, Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1–2 study, Lancet Oncol source
- Partly supportedcites [11] Loeb, 2022, Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial, Cancer Immunol Immunother sourceExperimental — accuracy not yet measured
The Discussion reports limited antitumour activity of avelumab monotherapy in children with relapsed or refractory solid tumours, consistent with other ICI monotherapy studies. The paper does not report limited activity for dual PD-(L)1 and CTLA-4 inhibitor regimens; its mention of nivolumab plus ipilimumab concerns an approval, not trial activity. (LLM, conf=0.89)
- Not checked — no full text of the sourcecites [12] Kudo, 2019, Scientific rationale for combination immunotherapy of hepatocellular carcinoma with anti–PD-1/PD-L1 and anti–CTLA-4 antibodies, Liver Cancer source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“durvalumab plus tremelimumab has demonstrated improved OS compared with sorafenib alone in adults with unresectable hepatocellular cancer (14).”
§ Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors > Introduction
What the sources say
- Supportedcites [14] Abou-Alfa, 2022, Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma, NEJM Evid source
The Discussion states that the tremelimumab–durvalumab STRIDE regimen significantly improved overall survival versus sorafenib in patients with unresectable hepatocellular carcinoma who had not previously received systemic therapy. The Superiority Analysis reports an overall-survival hazard ratio of 0.78 for that comparison. (LLM, conf=0.94)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In phase III trials, durvalumab plus tremelimumab administered with chemotherapy has demonstrated improved progression-free survival (PFS) and overall survival (OS) compared with chemotherapy alone in adults with metastatic non–small-cell lung cancer (NSCLC) (13)”
§ Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors > Introduction
What the sources say
- Supportedcites [13] Johnson, 2023, Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study, J Clin Oncol source
The Discussion reports that tremelimumab plus durvalumab and chemotherapy significantly improved both overall survival and progression-free survival versus chemotherapy alone. The paper identifies POSEIDON as a phase III study in first-line metastatic non–small-cell lung cancer. (LLM, conf=0.92)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
52 more claims · 5 with their cited sources checked
Create a free account to see all 123 claims and every source verdict.
- It may state two separate claims as one. 56
- Probably not a substantial claim. 15
- The quote only partly states this claim. 2
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| | Disease progression | 10 (0.9) | 7 (77.8) | 17 (85.0) |”
§ Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors > Results > Antitumor activity and survival endpoints
Reported 0.9 · recomputed 90.909091
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Other* | 11 (41.4) | 7 (33.3) | 18 (36.0) |”
§ Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors > Results > Patients
Reported 41.4 · recomputed 37.931034
Citations
Cites
Bagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189 · cited 1×
“Based on improved outcomes demonstrated with immune checkpoint inhibitors (ICIs) in adult patients across a variety of cancer types (4), ICI therapies have been investigated in children with solid tumors and lymphoma, including those with relapsed/ refractory disease (5 – 11).”
Cytotoxic CD8+ T cells in cancer and cancer immunotherapy
Raskov, H., Orhan, A., Christensen, J. P., & Gögenur, I. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01048-4 · Cited by 1,687 · cited 1×
“A robust expansion of proliferating CD8+ T cells is a critical response to immune-checkpoint inhibition leading to an enhanced adaptive immune response, speci fi cally due to the activation of exhausted T cells (18).”
Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Abou-Alfa, G. K., Lau, G., Kudo, M., Chan, S. L., Kelley, R. K., Furuse, J., Sukeepaisarnjaroen, W., Kang, Y.-K., Van Dao, T., De Toni, E. N., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2100070 · Cited by 1,576
Tawbi, H. A., Burgess, M., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Hu, J., D'Angelo, S., Attia, S., Riedel, R. F., Priebat, D. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30624-1 · Cited by 1,452 · cited 1×
“While previous pediatric studies of ICIs have demonstrated limited activity in osteosarcoma, there have been other single cases of durable partial responses reported in adult trials (21, 22).”
Green, M. R., Monti, S., Rodig, S. J., Juszczynski, P., Currie, T., O'Donnell, E., Chapuy, B., Takeyama, K., Neuberg, D., Golub, T. R., et al. (2010) · Blood · doi:10.1182/blood-2010-05-282780 · Cited by 1,305
Antonia, S., Goldberg, S. B., Balmanoukian, A., Chaft, J. E., Sanborn, R. E., Gupta, A., Narwal, R., Steele, K., Gu, Y., Karakunnel, J. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00544-6 · Cited by 602
Johnson, M. L., Cho, B. C., Luft, A., Alatorre-Alexander, J., Geater, S. L., Laktionov, K., Kim, S.-W., Ursol, G., Hussein, M., Lim, F. L., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00975 · Cited by 463
Suh, E., Stratton, K. L., Leisenring, W. M., Nathan, P. C., Ford, J. S., Freyer, D. R., McNeer, J. L., Stock, W., Stovall, M., Krull, K. R., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30800-9 · Cited by 373
Geoerger, B., Kang, H. J., Yalon-Oren, M., Marshall, L. V., Vezina, C., Pappo, A., Laetsch, T. W., Petrilli, A. S., Ebinger, M., Toporski, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30671-0 · Cited by 357 · cited 4×
“Geometric mean serum concentrations for durvalumab and tremelimumab in the dose-expansion phase are shown in Supplementary Figure 4; the complete summary of PK parameters for durvalumab and tremelimumab in the dose-expansion phase are summarized in Supplementary Tables 6, 7, respectively.”
InfluentialSelf-citationDavis, K. L., Fox, E., Merchant, M. S., Reid, J. M., Kudgus, R. A., Liu, X., Minard, C. G., Voss, S., Berg, S. L., Weigel, B. J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30023-1 · Cited by 337
Cited by
Combination epigenetic-targeted therapy increases the immunogenicity of poorly immunogenic sarcomasPreprint
Recho, A., Gatla, H. R., Resch, E. E., Phillips, M. J., Glavaris, S. A., Doucet, M., Looi, A. N. M., Barbato, M. I., Llosa, N. J., Koldobskiy, M. A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.18.733244
Self-citation
Metadata
- Authors
- Hargrave, D., Marshall, L. V., André, N., Krystal, J., Ladle, B. H., Robbins, K. A., Hois, S., Armstrong, J., & Donegan, S.
- Affiliations
- Great Ormond Street Hospital (GB)
- Institute of Cancer Research (GB)
- Pediatric Hematology and Oncology Department, Hôpital pour Enfant de La Timone, Assistance Publique - Hôpitaux de Marseille (AP-HM), and Reverse Molecular Pharmacology in Pediatric Oncology, Centre de Recherche en Cancérologie de Marseille (CRCM), Aix-Marseille Université, CNRS, INSERM
- Cohen Children's Medical Center (US)
- Johns Hopkins University (US)
- Global Patient Safety, Oncology, AstraZeneca
- Late-stage Development Oncology R&D, AstraZeneca
- Oncology Biometrics
- Oncology R&D, AstraZeneca
- Corresponding author
- Hargrave, Darren
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2026-05-15
- Volume
- 16
- Pages
- 1680081-1680081
- ISSN
- 2234-943X (ISSN-L)
- PMC
- PMC13218898
- OpenAlex
- W7161272841
- Semantic Scholar
- 9ba2ce9992b607e0dced0582a2f989c11c2fa160
- Cited by
- 1
- References
- 27
- Citations by year
- 2026: 1
- FWCI
- 2.94
- Type
- journal article
- Language
- en
- Update notices
- correction (2026-06-09)
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Oncology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- durvalumab, tremelimumab, PD-L1 inhibitors, CTLA-4 blockade, immune checkpoint inhibitors, combination immunotherapy, pediatric solid tumors, relapsed/refractory cancer, sarcoma, chordoma, renal cell carcinoma, dose-finding, recommended phase 2 dose, anticancer activity, treatment safety, immune cell activation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors. https://app.cochat.ai/papers/10.3389/fonc.2026.1680081
- The paper
- Hargrave, D., Marshall, L. V., André, N., Krystal, J., Ladle, B. H., Robbins, K. A., Hois, S., Armstrong, J., & Donegan, S. (2026). Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors. Frontiers in Oncology. https://doi.org/10.3389/fonc.2026.1680081
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.